How Particle Size Classification Drives Product Consistency and Quality in Complex Injectables

Pharmaceutical pipelines have shifted decisively toward complex drug delivery systems like long-acting injectables (LAIs), but this innovation poses new quality challenges. In LAIs and other complex delivery systems, product consistency and quality is no longer a narrow specification checked at batch release. For injectable products specifically, quality is inseparable from patient safety, dose accuracy, and predictable pharmacokinetics. A subtle change in particle size can lead to needle clogging, dose dumping, or inconsistent exposure profiles. This is why precise particle size classification is such a linchpin for the success of promising R&D formulations.

LAIs play an increasingly important part in improving patient adherence and therapeutic durability. Among the most widely adopted platforms are poly(lactic-co-glycolic acid) (PLGA)–based microspheres, engineered to release an active pharmaceutical ingredient (API) over weeks or months rather than minutes.

Particle size distribution (PSD) governs surface area-to-volume ratios in microsphere-based therapeutics. Smaller particles expose more surface area, accelerating polymer hydration and drug diffusion. The result is a pronounced initial burst release, which can compromise safety for potent APIs. Larger particles, by contrast, favour slower polymer erosion and more stable sustained-release phases.

Particle size also determines whether a formulation can be delivered at all. Oversized particles increase the risk of needle plugging, while excessive fines introduce a different hazard: rapid drug dumping and local toxicity. For clinicians and patients, injectability failures are not a manufacturing inconvenience but a point-of-care risk.

Relying solely on the median particle diameter (D50) masks these risks. It is the distribution tails (D10 and D90) that reveal whether fines or oversized particles threaten consistency. Controlling these extremes is essential for batch-to-batch homogeneity and for maintaining PSD as a true critical quality attribute rather than a descriptive metric.

Conventional microsphere processing often relies on sequential unit operations: classification, filtration, washing, and drying, each performed in separate pieces of equipment. Every transfer can introduce product loss, contamination risk, and particle attrition that can subtly distort PSD.

Manual handling compounds the challenge. Even in controlled cleanrooms, operator-dependent steps introduce variability. In aseptic processing, that variability can affect both sterility assurance and particle integrity, undermining reproducibility.

Formulations that behave predictably in a one-litre beaker often fail at production scale. Increased shear forces, altered flow paths, and longer processing times all reshape PSD during scale-up. Without engineered controls, scale becomes the enemy of consistency.

The PSL MicroSphere Refiner (MSR™) was designed to consolidate multiple steps into a single, closed system. Classification, filtration, de-watering, washing, and drying occur without intermediate transfers, reducing contamination risk and preserving particle size distribution integrity.

Interchangeable mesh porosity enables precise definition of size cut-offs, tailored to the target PSD. Multi-zone, pressure-driven filtration efficiently removes undersized fines and debris without subjecting particles to excessive mechanical stress.

Drying is where fragile polymer microspheres often suffer. The MSR™ addresses this through heated agitation to promote uniform cake formation without mechanical degradation, combined with low-vacuum, low-temperature control to protect thermally sensitive APIs and maintain polymer integrity.

Embedding Process Analytical Technology (PAT), such as inline particle size analysers and process cameras, enables real-time feedback. Deviations are detected as they occur, supporting first-time-right manufacturing rather than retrospective correction.

Modern systems must align with sub-visible particulate requirements while supporting electronic data integrity and automated traceability. Automation and audit-ready data capture are now baseline expectations rather than differentiators.

Closed processing protects both sides of the equation: maintaining asepsis for the product and providing containment for high-potency APIs that pose occupational exposure risks.

Consistency in complex injectables is the outcome of controlled environments, engineered classification, and a recognition that particle size is a mechanistic driver of quality rather than a downstream check.

By integrating precise particle size classification into a closed, scalable workflow, platforms like the MSR™ MicroSphere Refiner help transform microsphere-based injectables from difficult-to-process formulations into repeatable, high-yield commercial products. For manufacturers navigating the next generation of long-acting injectables, particle precision is foundational to patient trust and therapeutic success. If you are interested in reading more about this topic, refer to our article on how microsphere formulation works. Or, contact a member of the PSL team today with any questions.